Company Overview and News

4
Berjaya Land posts RM189.5mil loss

2018-06-28 thestar.com.my
According to a Bursa Malaysia filing, Berjaya Land also reported unfavourable foreign exchange translation effect due to the strengthening of the ringgit and lower share of profits from its associated companies
4219 BSMAF 1818

3
KLCI seen extending losses as global markets fizzle

2018-06-27 theedgemarkets
KUALA LUMPUR (June 28): The FBM KLCI is seen extending its losses today, in line with the overnight fizzle at most global markets, which sputtered after a slight rally.
7293 5738 4219 2127 7036 5158

3
Country Heights, TA Global, Berjaya Land, MGB, EA Technique, Gamuda, Yinson Holdings Bhd, Borneo Oil and Comfort Gloves

2018-06-27 theedgemarkets
KUALA LUMPUR (June 27): Based on corporate announcements and news flow today, stocks in focus for Thursday (June 28) may include the following: Country Heights Holdings Bhd, TA Global Bhd, Berjaya Land Bhd, MGB Bhd, EA Technique (M) Bhd, Gamuda Bhd, Yinson Holdings Bhd, Borneo Oil Bhd and Comfort Gloves Bhd.
5789 7293 5738 4219 2127 7036 5158

0
Berjaya Land ends FY18 in the red as forex rates, Sports Toto drag

2018-06-27 theedgemarkets
KUALA LUMPUR (June 27): Berjaya Land Bhd, which is controlled by tycoon Tan Sri Vincent Tan, wrapped up its financial year ended April 30, 2018 (FY18) with another quarter of net loss, due mainly to unfavourable foreign exchange rates, and lower profit contribution from its number forecast operator business.
4219

0
Trading ideas: Berjaya Land, MyEG, Cymao

2018-06-05 thestar.com.my
KUALA LUMPUR: Berjaya Land Bhd (BLand), MyEG Services Bhd and Cymao Holdings Bhd are among the stocks to watch out on Tuesday, according to JF Apex Research.
4219 5082

4
Berjaya Land sells stake in Vietnam firm for RM155mil

2018-06-04 thestar.com.my
PETALING JAYA: Berjaya Land Bhd (BLand) is selling its entire stake in Vietnam-based Berjaya Vietnam Financial Centre Ltd (BVFC Ltd) for RM154.86mil to the country’s biggest property developer.
4219 BSMAF 1818

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...